Based on the strong preclinical data Vicore Pharma’s strategy is to license its IPR to a pharmaceutical company at an early stage whilst maintaining a readiness to undertake development up until phase IIA investigations.
In parallel, company management estimates that further preclinical data on C21 will be presented continously as a result from ongoing preclinical research taking place in different research institutions.